Can-Fite BioPharma (CANF) Announces Receipt of EMA Orphan Drug Designation for CF102 as HCC Treatment
Tweet Send to a Friend
Can-Fite BioPharma (NYSE: CANF) announced the Company's oncology drug candidate, CF102, has been granted Orphan Drug Designation by the European ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
